Hyung Sujin, Han Boram, Jung Jaeyun, Kim Seung Tae, Hong Jung Yong, Park Se Hoon, Zang Dae Young, Park Joon Oh, Park Young Suk, Kim Kyoung-Mee, Kang Won Ki, Lee Jeeyun
Innovative Institute for Precision Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Division of Hematology-Oncology, Department of Medicine, Hallym University, Hallym Sacred Heart Hospital, Anyang, Republic of Korea.
J Oncol. 2022 Mar 18;2022:9714570. doi: 10.1155/2022/9714570. eCollection 2022.
Aberrations in the () gene, including genetic alterations and chromosomal rearrangements, lead to the development and progression of cancer with poor prognosis. However, the mechanisms underlying the FGFR2 signaling pathway to facilitate the development of FGFR2-targeted therapies have not been fully explored. Here, we examined the clinicopathological features of amplification and fusion in gastrointestinal tract/genitourinary tract cancers. amplification and fusion were identified in approximately 1.5% and 1.1% of all cancer types in 1,373 patients, respectively, with both amplification and fusion occurring together at a rate of approximately 0.6%. Of all cancer types screened, gastric cancer (GC) was the most common cancer type with amplification (87.5% of all amplification case) or fusion (46.7% of all cases). In addition, alteration had poorer overall survival (OS, 13.7 months vs. 50.2 months, = 0.0001) and progression-free survival (PFS, 5.6 months vs. 11.4 months, = 0.0005) than did those without FGFR2 alteration, respectively. Taken together, our data underscore to screen solid cancer patients for FGFR2 aberrations in oncology clinic.
（）基因的畸变，包括基因改变和染色体重排，会导致预后不良的癌症发生和发展。然而，FGFR2信号通路促进FGFR2靶向治疗发展的潜在机制尚未得到充分探索。在此，我们研究了胃肠道/泌尿生殖道癌症中FGFR2扩增和融合的临床病理特征。在1373例患者的所有癌症类型中，分别约有1.5%和1.1%检测到FGFR2扩增和融合，FGFR2扩增和融合同时出现的比例约为0.6%。在所有筛查的癌症类型中，胃癌（GC）是FGFR2扩增（占所有FGFR2扩增病例的87.5%）或融合（占所有病例的46.7%）最常见的癌症类型。此外，与无FGFR2改变的患者相比，FGFR2改变的患者总生存期（OS，13.7个月对50.2个月，P = 0.0001）和无进展生存期（PFS，5.6个月对11.4个月，P = 0.0005）更差。综上所述，我们的数据强调在肿瘤学临床中对实体癌患者进行FGFR2畸变筛查。
